Toripalimab and capecitabine after chemo-radiation for high-risk nasopharyngeal cancer
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This trial tests whether adding the immunotherapy drug toripalimab to the chemotherapy pill capecitabine after standard treatment helps prevent nasopharyngeal cancer from coming back. It is for people with high-risk features who have already had chemo and radiation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have high-risk nasopharyngeal cancer (cancer in the back of the nose/throat) and it must not have spread to other parts of the body.
- You must have already completed 2 to 3 rounds of chemotherapy and radiation therapy together.
- You should be between 18 and 70 years old and in generally good health (able to do your daily activities without much difficulty).
- You cannot have had prior treatment with a PD-1 inhibitor (a type of immunotherapy) or have active autoimmune diseases.
- Your blood tests must show adequate kidney and liver function, and you must not have serious infections or heart/lung problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment for advanced nasopharyngeal cancer. You will get chemotherapy and radiation, followed by maintenance therapy with an immunotherapy drug called toripalimab to help your immune system fight the cancer.
This trial studies whether adding toripalimab to radiation plus chemotherapy can improve outcomes for people with advanced nasopharyngeal cancer. It also looks at tumor markers (like PD-L1) using stored tumor tissue or a new biopsy.
This trial tests whether taking the chemo tablet capecitabine after standard chemoradiation can help prevent cancer from coming back, and whether adding an immune therapy (a PD-1 antibody) improves results. It is for people with high-risk nasopharyngeal (throat) cancer whose main treatment has already finished.
This trial tests a combination treatment (chemotherapy before, then chemotherapy with radiation) for advanced nasopharyngeal cancer that hasn't spread to distant sites. The goal is to improve survival and control of the disease.
This trial tests a combination of two drugs—tislelizumab (an immunotherapy that helps your immune system fight cancer) and capecitabine (a chemo pill taken daily)—as maintenance therapy after initial chemotherapy for high-risk nasopharyngeal cancer. The goal is to see if this approach can lower the chance of cancer coming back.
This Phase 2 trial studies whether adding toripalimab (an immune therapy) to radiation can control nasopharyngeal cancer that has spread only to a few places. It may help by boosting the immune system while the radiation treats the tumor sites.
Hear when a new Nasopharyngeal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.